Pazopanib: In advanced renal cell carcinoma

BioDrugs

Volumn 24, Issue 5, 2010, Pages 279-286

  Sanford, Mark ^a   Keating, Gillian M ^a  

^a Wolters Kluwer Health   (New Zealand)

Author keywords

Adis Drug Profiles; Pazopanib, general; Renal cancer; Research and development

Indexed keywords

CAFFEINE; CYTOKINE; DEXTROMETHORPHAN; IRINOTECAN; KETOCONAZOLE; MIDAZOLAM; OMEPRAZOLE; PACLITAXEL; PAZOPANIB; PLACEBO; RIFAMPICIN; ROSUVASTATIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VOTRIENT; WARFARIN;

ABDOMINAL PAIN; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HAIR COLOR; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; IC 50; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHRECTOMY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

ANTICARCINOGENIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SULFONAMIDES;

EID: 77956167433     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11205480-000000000-00000     Document Type: Review

References (22)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. NEngl J Med 1996 Sep 19; 335 (12): 865-875
2. Chow W-H, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008; 14 (5): 288-301
3. Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol 2009 May; 20 Suppl. 4: iv81-2
4. Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int 2009 Dec; 104 (11): 1585-1589
5. Brugarolas J. Renal-cell carcinoma: molecular pathways and therapies. N Engl J Med 2007 Jan 11; 356 (2): 185-187
6. Bukowski RM, Yasothan U, Kirkpatrick P. Pazopanib. Nat Rev Drug Discov 2010 Jan; 9 (1): 17-18
7. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Cancer Netw 2009 Jun; 7 (6): 618-630
8. National Comprehensive Cancer Network. Clinical practice guidelines in on-cology: kidney cancer [online]. Available from URL: http://www.nccn.org/ professionals/physician-gls/PDF/kidney.pdf [Accessed 2010 Apr 20]
9. LjungbergB,CowanN, Hanbury DC,et al. Guidelines on renal cell carcinoma. European Association of Urology [online]. Available from URL: http://www. uroweb.org/gls/pdf/Renal%20Cell%20Carcinoma%202010.pdf [Accessed 2010 Jun 16]
10. GlaxoSmithKline. Votrient (pazopanib): prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 022465lbl.pdf [Accessed 2010 Apr 20]
11. European Medicines Agency. Votrient (pazopanib): summary of product characteristics [online]. Available from URL:http://www.nelm.nhs.uk/en/Original- search/?query=pazopanib [Accessed 2010 Jul 5]
12. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009 Nov 17; 101 (10): 1717-1723
13. FDA Centre for Drug Evaluation and Research. Votrient (pazopanib): sum-mary review [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2009022465s000SumR.pdf [Accessed 2010 Mar 21]
14. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010 Feb 20; 28 (6): 1061-1068
15. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010 Jan 20; 28 (3): 475-480
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000 Feb 2; 92 (3): 205-216
17. Hutson TE, Davis ID, Machiels JP, et al. Predictive and prognostic factors in phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angio-genesis inhibitor [abstract no. 5780 plus oral presentation]. 33rd Congress of the European Society for Medical Oncology; 2008 Sep 12-16; Stockholm
18. Heymach JV, Tran HT, Fritsche HA, et al. Lower baseline levels of plasma hepatocyte growth factor, IL-6, and IL-8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib [abstract no. A11 with poster]. 21st American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston (MA)
19. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [online]. Available from URL: http://ctep.cancer.gov/protocolDevelopment/electronic-applica tions/docs/ctcaev3.pdf [Accessed 2010 Apr 29]
20. Xu C, Reck B, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is asso-ciated with Gilbert's syndrome UGT1A1 polymorphism [abstract no. P-1114]. 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology; 2009 Sep 20-24; Berlin
21. GlaxoSmithKline. Pazopanib versus sunitinib in the treatment of locally ad-vanced and/or metastatic renal cell carcinoma (COMPARZ) [ClinicalTrials. gov identifier NCT00720941]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/results? term=NCT00720941 [Accessed 2010 May 4]
22. GlaxoSmithKline. Patient preference study of pazopanib versus sunitinib in advanced or metastatic kidney cancer (PISCES) [ClinicalTrials.gov identifier NCT01064310]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/results?term=NCT01064310 [Accessed 2010 Jun 16]